GET THE APP

A Case of a Rare STRN-ALK Fusion in Esophagus Adenocarcinoma Exhibits Excellent Response to Crizotinib | SciTechnol

Clinical Oncology: Case Reports.

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report, Clin Oncol Case Rep Vol: 4 Issue: 2

A Case of a Rare STRN-ALK Fusion in Esophagus Adenocarcinoma Exhibits Excellent Response to Crizotinib

Xiaofei Zhang1, Xiao Chu2, Kuaile Zhao2 and Weixin Zhao1*

1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, China

2Department of Oncology, Shanghai Medical College, China

*Corresponding Author:
Weixin Zhao
Fudan University Shanghai Cancer Center
270 Dongan Road, Xuhui, Shanghai, China
E-mail: zwx_zhxf@163.com

Received: November 12, 2020 Accepted: January 31, 2021 Published: February 20, 2021

Citation: Zhang X, Chu X, Zhao K, Zhao W. (2021) A Case of a Rare STRN-ALK Fusion in Esophagus Adenocarcinoma Exhibits Excellent Response to Crizotinib. Clin Oncol Case Rep 4:2

Abstract

We present a first case of a rare STRN-ALK fusion in esophagus adenocarcinoma exhibits excellent response to crizotinib. A 36-year-old male disgnosed of esophagus adenocarcinoma. The patient recieved six cycles of new neoadjuvan-chemotherapy with the regimen of paclitaxel plus cisplatin and neoadjuvant radiotherapy with the dose of 45GY/25f. Ten months later, he received four cycles of chemotherapy with the regimen of paclitaxel plus cisplatin because that radiological examination revealed two emerging nodules in the left inner lobe of the liver and progress of nodular thickeningness of bilateral interlobar pleura and left pleura..Four months later, radiological examination revealed progression in the liver and in esophagus. Patient refused third line chemotherapy and ask for gene testing. Amplification refractory mutation system analysis revealed STRN-ALK fusion in both plasma and tissue and the patient requests to try crizotinib. To date, his liver and left pleura lesions recessed significantly. and his symptoms were greatly relieved after using crizotinib with 22-month PFS and 43-month OS.

Keywords: Chemotherapy; Radiological; Esophagus; Crizotinib; Mutation

Track Your Manuscript

Google scholar citation report